WO2000050066A1 - Treatment of infertility - Google Patents

Treatment of infertility Download PDF

Info

Publication number
WO2000050066A1
WO2000050066A1 PCT/DK2000/000074 DK0000074W WO0050066A1 WO 2000050066 A1 WO2000050066 A1 WO 2000050066A1 DK 0000074 W DK0000074 W DK 0000074W WO 0050066 A1 WO0050066 A1 WO 0050066A1
Authority
WO
WIPO (PCT)
Prior art keywords
hormone
antagonist
agonist
oocytes
mas
Prior art date
Application number
PCT/DK2000/000074
Other languages
French (fr)
Inventor
Christian GRØNDAHL
Thomas Høst HANSEN
Alexander Rübig
Christa Hegele-Hartung
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to PL00350221A priority Critical patent/PL350221A1/en
Priority to JP2000600676A priority patent/JP2002537349A/en
Priority to BR0008468-9A priority patent/BR0008468A/en
Priority to KR1020017009383A priority patent/KR20010093280A/en
Priority to EP00906178A priority patent/EP1156822B1/en
Priority to DE60025905T priority patent/DE60025905T2/en
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Priority to IL14372900A priority patent/IL143729A0/en
Priority to CA002362940A priority patent/CA2362940A1/en
Priority to AU27941/00A priority patent/AU2794100A/en
Priority to US09/528,610 priority patent/US6585982B1/en
Publication of WO2000050066A1 publication Critical patent/WO2000050066A1/en
Priority to NO20014093A priority patent/NO20014093L/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0608Germ cells
    • C12N5/0609Oocytes, oogonia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/24Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30Hormones
    • C12N2501/38Hormones with nuclear receptors
    • C12N2501/39Steroid hormones
    • C12N2501/392Sexual steroids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2517/00Cells related to new breeds of animals
    • C12N2517/10Conditioning of cells for in vitro fecondation or nuclear transfer

Definitions

  • This invention relates to an improved method of in vitro fertilisation (hereinafter designated IVF).
  • IVF of human oocytes has become commonly used for the treatment of female and male subfertility.
  • the standard IVF treatment includes a long phase of hormone stimulation of the female patient, e.g. 30 days, which is initiated by suppressing the patient's own follicle stimulating hormone (hereinafter designated FSH) and luteinis- ing hormone (hereinafter designated LH) by gonadotropin releasing hormone (hereinafter designated GnRH), and this is followed by injections of exogenous gonad- otropins, e.g. FSH and/or LH, in order to ensure development of multiple preovula- tory follicles and aspiration of multiple in vivo matured oocytes immediately before ovulation.
  • FSH follicle stimulating hormone
  • LH gonadotropin releasing hormone
  • exogenous gonad- otropins e.g. FSH and/or LH
  • the aspirated oocyte is subsequently fertilised in vitro and cultured, typi- cally for three days before transferral back into the uterus at the 4-8 cell stage.
  • Continuous efforts have been made to optimise and simplify this procedure. Nevertheless, the overall pregnancy rate cannot be increased significantly over about 20% with the current treatment modalities.
  • 7.2 oocytes out of 11.5 aspirated oocytes per patient had undergone resumption of meiosis immediately before fertilisation, only 4.3 oocytes were fertilised and only 2.2 oocytes reached the 8-cell embryo stage after fertilisation and in vitro culture (ESHRE, Edinburgh, 1997).
  • FF-MAS 4,4-dimethyl-5 ⁇ -cholesta-8,14,24-triene- 3 ⁇ -ol
  • MAS compounds designates compounds which mediate the meiosis of oocytes. More specifically, MAS compounds are compounds which in the test described in Example 1 below has a percentage germinal vesicle breakdown (hereinaf- ter designated GVB) which is significantly higher than the control. Preferred MAS compounds are such having a percentage GVB of at least 50%, preferably at least 80%. Examples of MAS compounds are mentioned in WO 96/00235, 96/27658, 97/00884, 98/28323, 98/54965 and 98/55498, more specifically in Claim 1 thereof.
  • WO 95/000265 some potential meiosis regulating substances were tested on immature female mice. 48 hours before the test animal were killed by cervical dislocation, they were given a single injection of human menopausal gonadotropin containing 20 IU FSH and 20 IU LH. The ovaries were removed, placed in a hypoxanthine medium and freed of extraneous tissue. Then, the oocytes were punctured out of the follicles, freed from cumulus cells and cultured in a medium containing a meiosis regulating derivative.
  • One object of the present invention is to treat human infertility.
  • Another object of the present invention is to improve the maturation of human oocytes.
  • Another object of the present invention is to improve the synchrony of nu- clear, cytoplasmic and/or membranous oocyte maturation.
  • Another object of the present invention is to improve the fertility of oocytes.
  • Another object of the present invention is to improve the rate of implantation of oocytes by human in vitro maturation and fertilisation.
  • Another object of the present invention is to diminish the incidence of human preembryos with chromosome abnormalities (aneuploidy).
  • Another object of the present invention is to improve the cleavage rate of human preembryos.
  • Another object of the present invention is to improve the quality of human preembryos.
  • the present invention relates to a method for human in vitro fertilisation wherein a woman, within a consecutive period of 30 days, is treated with a hypotha- lamic hormone and/or a pituitary hormone or an agonist or antagonist thereof or an active derivative thereof where after oocytes are aspirated and actively final matured or the oocyte maturation is synchronised in vitro in contact with a MAS compound.
  • a hypotha- lamic hormone and/or a pituitary hormone or an agonist or antagonist thereof or an active derivative thereof where after oocytes are aspirated and actively final matured or the oocyte maturation is synchronised in vitro in contact with a MAS compound.
  • the eggs are stimulated by treating the woman with GnRH, e.g. Synarel (400-600 ⁇ g per day).
  • GnRH e.g. Synarel (400-600 ⁇ g per day).
  • the eggs are stimulated by treating the woman with FSH, e.g. Gonal-F, Puregon or Humegon (150-400 IU per day).
  • FSH e.g. Gonal-F, Puregon or Humegon
  • the eggs are stimulated by treating the woman with hCG, e.g. Pregnyl or Profasi (2000-5000 IU per day).
  • hCG e.g. Pregnyl or Profasi (2000-5000 IU per day).
  • the eggs are maturated with a MAS compound in order to stimulate the meiosis.
  • the con- centration of MAS compound may be in the range about 0J-100 ⁇ mol per litre, e.g. 10-20 ⁇ mol per litre.
  • the time for this maturation step may be in the range around 1- 60 hours.
  • the maturation of the oocytes with the MAS compound is for a duration of about 1-15 hours, preferably about 6 hours.
  • the maturation of the oocytes with the MAS compound is for duration of about 15-60 hours.
  • oestrogen e.g., oestrogen valerate (2 x 10 mg daily).
  • progestogen e.g., Progestane vagetoria
  • the duration of this treatment will be individually designed per patient. The doctor can chose among a variety of oestrogens and pro- gestogens.
  • MAS add-on to the existing IVF protocol to improve efficacy by mediating a final or complete maturation or synchrony in the oo- cyte.
  • MAS can be used to rescue oocytes in cycles that otherwise would be cancelled due to apparent FSH hyper response.
  • the responsible clinician would consider cancellation based on the estradiol profile, ultra- sonography (PCO like response) thus avoiding the hCG treatment.
  • the oocytes are aspirated at the time around day 15-16 substituting hCG treatment.
  • the above IVF is performed the usual way. Since one expects that by the traditional IVF procedure the eggs had been matured sufficiently, one would not expect that it would have any additional effect to add this additional maturation step.
  • the MAS compound is added to the culture medium used.
  • the amount of the MAS compound is in the range from about 0.01 to about 100 ⁇ M, preferably in the range from about 0.1 to about 100 ⁇ M.
  • a preferred reason for treating a woman, within a consecutive period of 30 days, with a hypothalamic hormone and/or a pituitary hormone or an agonist or antagonist thereof or an active derivative is to obtain multiple preovulatory follicles.
  • Hypothalamic hormones are hormones present in the human hypothalamus.
  • Pituitary hormones are hormones present in the human pituitary gland.
  • Gonadotropic hormones are hormones secreted by the anterior lobe of the pituitary in vertebras and by mammalian placenta, which control the activity of gonads. Chemically, they are glycoproteins.
  • gonadotropic hormones are FSH, LH and chorion gonadotropin, e.g. human chorion gonadotropin (hereinafter designated hCG).
  • FSH stimulates growth of ovarian follicles and their oocytes in ovary and the formation of spermatozoa in testis.
  • FSH can, e.g., be menopausal FSH or recombinant FSH.
  • LH activates the oestrogen-producing tissue of the ovaries to produce progesterone, probably promotes the final stages of the development of ovarian follicles, initiates the final oocyte maturation, induces ovulation and in mammals initiates cor-
  • the present invention relates to a method or use wherein the consecutive period of 30 days within which the woman is treated with a hypotha- lamic hormone and/or a pituitary hormone or an agonist or antagonist thereof or an active derivative thereof is at least about 7 days, preferably at least about 10 days, more preferred at least about 14 days.
  • the present invention relates to a method or use wherein the woman is treated for infertility, and/or for improving the maturation of her oocytes, and/or for improving the synchrony of nuclear, cytoplasmic and/or membranous oocyte maturation, and/or for improving the fertility of her oocytes, and/or for improving the rate of implantation by human in vitro maturation and fertilisation
  • the present invention relates to a method or use wherein the consecutive period is one menstrual cycle.
  • the present invention relates to a method or use wherein the maturation of the oocytes with the MAS compound is for a duration of about 15 to about 60 hours.
  • the present invention relates to a method or use wherein preovulatory follicles are induced to lutenise with a luteinising hormone (LH) or an agonist or antagonist thereof or an active derivative thereof and/or human chorion gonadotropin (HCG) or an agonist or antagonist thereof or an active derivative thereof.
  • LH luteinising hormone
  • HCG human chorion gonadotropin
  • the present invention relates to a method or use wherein the maturation of the oocytes with the MAS compound is for a duration of about 1 to about 15 hours, preferably about 6 hours.
  • the present invention relates to a method or use wherein the dosage of MAS compound used is about 0.01 to about 100 ⁇ mol per litre, preferably about 0.1 to about 100 ⁇ mol per litre.
  • the present invention relates to a method or use wherein the MAS compound is one of the compounds mentioned in WO 96/00235, 96/27658, 97/00884, 98/28323, 98/54965 and 98/55498, more specifically compounds mentioned in Claim 1 thereof.
  • the present invention relates to a method or use wherein the MAS compound is FF-MAS.
  • the present invention relates to the use of a hypothalamic hormone and/or a pituitary hormone or an agonist or antagonist thereof or an active derivative thereof in the manufacture of a hormone product which is to be administered to a woman who, within a consecutive period of 30 days, is treated with a hypothalamic hormone and/or a pituitary hormone or an agonist or antagonist thereof or an active derivative thereof, and from whom, immediately after said period, one or more oocytes are aspirated, where after said oocyte(s) is/are cultivated in a convenient medium containing a MAS compound as defined herein, where after said oocyte(s) is/are fertilised with human sperm, and where after the resulting embryo(s) is/are transferred to a woman.
  • the present invention relates to the use of a hypothalamic hormone and/or a pituitary hormone or an agonist or antagonist thereof or an active derivative thereof and of a MAS compound for the manufacture of a medicament for the treatment of human in vitro fertilisation wherein a hypothalamic hormone and/or a pituitary hormone or an agonist or antagonist thereof or an active derivative thereof is, within a consecutive period of 30 days, used to treat a women and, thereafter, the MAS compound is used in an in vitro oocyte maturation of the egg or eggs retrieved from this woman.
  • the present invention relates to a pharmaceutically kit in unit dosage form for use by in vitro fertilisation comprising separate unit dosages, said kit comprising separate dosage units for sequential daily administration of a hypothalamic hormone and/or a pituitary hormone or an agonist or antagonist thereof or an active derivative thereof for sequential daily administration and 1 dosage units of a MAS compound.
  • This kit may have the preferred features described above.
  • Oocytes were obtained from immature female mice (C57BL/6J x DBA/2J F1 , Bom- holtgaard, Denmark) weighing 13-16 grams, that were kept under controlled tem- perature (20-22°C), light (lights on 06.00-18.00) and relative humidity (50-70%).
  • the mice received an intra-peritoneal injection of 0.2 ml gonadotropins (Gonal-F, Serono) containing 20 IU FSH and 48 hours later the animals were killed by cervical dislocation.
  • the ovaries were dissected out and the oocytes were isolated in Hx-medium (see below) under a stereomicroscope by manual rupture of the follicles using a pair of 27 gauge needles.
  • Spherical oocytes displaying an intact germinal vesicle hereinafter designated GV
  • CEO cumulus enclosed oocytes
  • NO naked oocytes
  • SUBST ⁇ UTE SHEET (RULE 26) minimum essential medium ( ⁇ -MEM without ribonucleosides, Gibco BRL, Cat. No. 22561 ) supplemented with 3 mg/ml bovine serum albumin (BSA, Sigma Cat. No. A- 7030), 5 mg/ml human serum albumin (HSA, Statens Seruminstitut, Denmark), 0.23mM pyruvate (Sigma, Cat. No S-8636), 2 mM glutamine (Flow Cat. No. 16-801 ), 100 lU/ml penicillin and 100 ⁇ g/ml streptomycin (Flow, Cat No. 16-700). This medium was supplemented with 3 mM hypoxanthine (Sigma Cat. No. H-9377) and designated Hx-medium.
  • the oocytes were rinsed three times in Hx-medium and oocytes of uniform size were divided into groups of CEO and NO. CEO and NO were cultured in 4-well multidishes (Nunclon, Denmark) in which each well contained 0.4 ml of Hx-medium and the compound to be tested in a concentration of 10 ⁇ M.
  • One control well i.e., 35-45 oocytes cultured in identical medium with no addition of test compound
  • was always cultured simultaneously with 3 test wells 35-45 oocytes per well supplemented with test compound).
  • the oocytes were cultured in a humidified atmosphere of 5% C0 2 in air for
  • % GVB ((number of GVB + number of PB)/ total number of oocytes) X 100.
  • the hormonal treatment can be a short or long gonadotropin based treatment with or without pituitary down regulation or with and without the use of GNRH antagonist and with or without the use of hCG. Future appropriate hormonal therapies designed for IVF can also be used.
  • Medium to full size follicles size 10 to 25 mm, preferential 16 to 20 mm follicles
  • the aspirated fluid will be searched for cumulus oocytes complexes (COC) and once identified under the stereomicroscope (with or without the use of embryo filters), the COC will be placed in culture.
  • COC cumulus oocytes complexes
  • the exposure to FF-MAS can vary from 1 to 60 hours, preferentially from 4 to 30 hours, and can be before, under and up to 24 hours after fertilisation.
  • oocyte culture media or media components known to the skilled worker can be used.
  • Human serum albumin (HSA) may or may not be added to the medium. If added, it can be in a concentration of 0.1 to 100 mg/ml, preferentially 5 to 15 mg/ml or 0.5 to 1.5 % volume/volume.
  • the formulation of FF-MAS may be in the form of an ethanol stock solution, DMSO or other organic solvent solution or it may be in form of FF-MAS/HSA dry coated wells ready to use just by adding the appropriate culture medium.
  • the concentration of FF-MAS may vary from 0J ⁇ M to 100 ⁇ M, preferentially 10 to 30 ⁇ M.
  • the oocytes may be fertil- ised by conventional IVF or by intracytoplasmatic sperm injection (ICSI) or by future appropriate fertilisation methods leading to fertilised zygotes.
  • the developing embryo may be transferred on day 1 to day 6 after fertilisation, preferentially on day 2 to 3, either as single egg transfer or multiple egg transfer.
  • the patient can receive progesterone and/or oestrogen therapy before and after the egg transfer in individually designed protocols to prime and sustain appropriate receptive endometrial lineage.
  • the patient underwent down regulation with recombinant FSH with an aver- age daily dose of 225 IU starting on Day 1 or 2 of the current cycle and used a GnRH antagonist, i.e., Cetrorelix (1 mg daily, subcutaneously, one shot), in the current cycle. At least 3 follicles of 17 mm or more were present at the time of administering hCG, i.e., Profasi (10.000 IU, one shot).
  • hCG i.e., Profasi (10.000 IU, one shot
  • oocyte culture system containing standard in vitro fertilization (IVF) media (IVF 20 (which is available from Scandinavian IVF Science AB, Gothenburg, Sweden)) supplemented with human serum albumin (0.8%) and FF- MAS (5 ⁇ M). All oocytes were cultured under normal conditions at 37°C in the incu- bator. Each oocyte was cultured in one well in a four-chamber culture dish as culture media system. The duration of exposure to the culture media with treatment was 4 hours ( ⁇ 30 minutes) before intracytoplasmic sperm injection (hereinafter designated ICSI) and 20 hours ( ⁇ 1 hour) after ICSI in the above IVF 20 medium.
  • ICSI intracytoplasmic sperm injection
  • Preembryos were evaluated for cleavage stage and fragmentation / morphology at 1 , 2 and 3 days post ICSI. After 3 days of culture, a selection of the best preembryos, typically two preembryos, was replaced to the female patient.
  • the female patient received an estrogen, i.e., Estrofem (6 mg/daily), and a progesterone, i.e. Utrogestan (600 mg/daily, micronized, vaginal suppository), to render the endometrium lining the patient uterus responsive and ready for allowing implantation of the transferred eggs.
  • Estrofem i.e., Estrofem
  • Utrogestan 600 mg/daily, micronized, vaginal suppository
  • GnRH analog i.e., Synarel (nasal spray, two puffs daily)
  • FSH recombinant FSH with an average daily dose of 225 IU.
  • Follicles were aspirated and metaphase II oocytes were cultured in oocyte culture system containing standard in vitro fertilization (IVF) media (IVF 20 (which is available from Scandinavian IVF Science AB, Gothenburg, Swe-
  • SUBST ⁇ UTE SHEET (RULE 26) den)) supplemented with human serum albumin (0.8%) and FF-MAS (5 ⁇ M). All oocytes were cultured under normal conditions at 37°C in the incubator. Each oocyte was cultured in one well in a four-chamber culture dish as culture media system. The duration of exposure to the culture media with treatment was 4 hours (+30 minutes) before intracytoplasmic sperm injection (ICSI) and 20 hours ( ⁇ 1 hour) after ICSI in the above IVF 20 medium. Preembryos were evaluated for cleavage stage and fragmentation / morphology at 1 , 2 and 3 days post ICSI.
  • ICSI intracytoplasmic sperm injection

Abstract

In vitro fertilisation can be improved by adding a meiosis activating compound.

Description

TREATMENT OF INFERTILITY
FIELD OF THIS INVENTION
This invention relates to an improved method of in vitro fertilisation (hereinafter designated IVF).
BACKGROUND OF THIS INVENTION
Since the first IVF pregnancy was delivered in 1978, this procedure has resulted in thousands of pregnancies and opened a vast new frontier of research and treatment for the infertile couples. Still, there is a significant need for improved infertility treatment modalities today. It is presumed that about one out of seven couples experience problems with subfertility or infertility.
IVF of human oocytes has become commonly used for the treatment of female and male subfertility. The standard IVF treatment includes a long phase of hormone stimulation of the female patient, e.g. 30 days, which is initiated by suppressing the patient's own follicle stimulating hormone (hereinafter designated FSH) and luteinis- ing hormone (hereinafter designated LH) by gonadotropin releasing hormone (hereinafter designated GnRH), and this is followed by injections of exogenous gonad- otropins, e.g. FSH and/or LH, in order to ensure development of multiple preovula- tory follicles and aspiration of multiple in vivo matured oocytes immediately before ovulation. The aspirated oocyte is subsequently fertilised in vitro and cultured, typi- cally for three days before transferral back into the uterus at the 4-8 cell stage. Continuous efforts have been made to optimise and simplify this procedure. Nevertheless, the overall pregnancy rate cannot be increased significantly over about 20% with the current treatment modalities. In a large European survey of IVF patients, it was found that 7.2 oocytes out of 11.5 aspirated oocytes per patient had undergone resumption of meiosis immediately before fertilisation, only 4.3 oocytes were fertilised and only 2.2 oocytes reached the 8-cell embryo stage after fertilisation and in vitro culture (ESHRE, Edinburgh, 1997). Due to the very unpredictable quality of the state of the art embryos today, more than one embryo has to be transferred just to give a reasonable chance of success. Therefore, it is common to transfer 2-3 embryos (up to 5 embryos in some countries), which carries the very large side effect of multiple pregnancies with great discomfort and risk to both patient and children. Moreover, it has been estimated that the increased health care expenses due to multiple birth (twins, triplets etc.) is exceeding the entire IVF expenses.
Hence, there are several disadvantages with the current treatment, the four most notable being:
1. the risk of ovarian hyperstimulation with injecting gonadotropins which is a potential fatal condition that requires hospitalisation,
2. multiple pregnancies (50-1.000 times the normal frequency of twins and triplets, respectively),
3. the existence of considerable patient segments that do not tolerate the current method due to, e.g. polycystic ovarian syndrome and many diabetics,
4. a potential long-term cancer risk.
Furthermore, weight gain, bloating, nausea, vomiting, labile mood and other patient discomforts together with patient reluctance to inject themselves are reported as disadvantages.
It is known from WO 96/00235 that certain sterol derivatives can be used for regulating meiosis. An example of such a sterol is 4,4-dimethyl-5α-cholesta-8,14,24-triene- 3β-ol (hereinafter designated FF-MAS).
Herein, the term MAS compounds designates compounds which mediate the meiosis of oocytes. More specifically, MAS compounds are compounds which in the test described in Example 1 below has a percentage germinal vesicle breakdown (hereinaf- ter designated GVB) which is significantly higher than the control. Preferred MAS compounds are such having a percentage GVB of at least 50%, preferably at least 80%. Examples of MAS compounds are mentioned in WO 96/00235, 96/27658, 97/00884, 98/28323, 98/54965 and 98/55498, more specifically in Claim 1 thereof.
In WO 95/000265, some potential meiosis regulating substances were tested on immature female mice. 48 hours before the test animal were killed by cervical dislocation, they were given a single injection of human menopausal gonadotropin containing 20 IU FSH and 20 IU LH. The ovaries were removed, placed in a hypoxanthine medium and freed of extraneous tissue. Then, the oocytes were punctured out of the follicles, freed from cumulus cells and cultured in a medium containing a meiosis regulating derivative.
At present, in vitro maturation in humans has proven highly unsuccessful despite substantial interest and clinical efforts.
One object of the present invention is to treat human infertility.
Another object of the present invention is to improve the maturation of human oocytes.
Another object of the present invention is to improve the synchrony of nu- clear, cytoplasmic and/or membranous oocyte maturation.
Another object of the present invention is to improve the fertility of oocytes.
Another object of the present invention is to improve the rate of implantation of oocytes by human in vitro maturation and fertilisation.
Another object of the present invention is to diminish the incidence of human preembryos with chromosome abnormalities (aneuploidy).
Another object of the present invention is to improve the cleavage rate of human preembryos.
Another object of the present invention is to improve the quality of human preembryos. SUMMARY OF THIS INVENTION
It has now, surprisingly, been found that the IVF can be improved substantially when a MAS compound is added at the stage in the usual method of performing in vitro fertilisation where one would expect that the maturation had taken place in vivo.
Briefly, the present invention relates to a method for human in vitro fertilisation wherein a woman, within a consecutive period of 30 days, is treated with a hypotha- lamic hormone and/or a pituitary hormone or an agonist or antagonist thereof or an active derivative thereof where after oocytes are aspirated and actively final matured or the oocyte maturation is synchronised in vitro in contact with a MAS compound. Preferred embodiments of this invention are those stated in the sub claims below.
DETAILED DESCRIPTION OF THIS INVENTION
Referring to the female cycle, on way of performing the treatment of this invention is as follows:
Around day 21 in one cycle to around day 15 in the following cycle: The eggs are stimulated by treating the woman with GnRH, e.g. Synarel (400-600 μg per day).
Around days 6-15 in the second cycle: The eggs are stimulated by treating the woman with FSH, e.g. Gonal-F, Puregon or Humegon (150-400 IU per day).
Around days 15-16 in the second cycle: The eggs are stimulated by treating the woman with hCG, e.g. Pregnyl or Profasi (2000-5000 IU per day).
Around day 18 in the second cycle: The eggs are retrieved from the woman.
Around day 18-19 in the second cycle: The eggs are maturated with a MAS compound in order to stimulate the meiosis. In this additional maturation step, the con- centration of MAS compound may be in the range about 0J-100 μmol per litre, e.g. 10-20 μmol per litre. The time for this maturation step may be in the range around 1- 60 hours. If the preovulatory follicles are induced to luthenise with a lutenising hormone or an agonist or antagonist thereof or an active derivative thereof and/or hu- man chorion gonadotropins or an agonist or antagonist thereof or an active derivative thereof, the maturation of the oocytes with the MAS compound is for a duration of about 1-15 hours, preferably about 6 hours. If, however, preovulatory follicles are not induced to lutenise with a lutenising hormone or an agonist or antagonist thereof or an active derivative thereof and/or human chorion gonadotropins or an agonist or an- tagonist thereof or an active derivative thereof, the maturation of the oocytes with the MAS compound is for duration of about 15-60 hours.
Around days 19-21 in the second cycle: The eggs are fertilised in vitro.
From the day before aspiration, the woman will receive an oestrogen, e.g., oestrogen valerate (2 x 10 mg daily). Two days later, she will also receive a progestogen, e.g., Progestane vagetoria, daily, which will render the lining of the uterus more prone to receive the future embryos. The duration of this treatment will be individually designed per patient. The doctor can chose among a variety of oestrogens and pro- gestogens.
Around day 21 in the second cycle: One or more embryos are transferred to the woman's uterus.
The description above is designated MAS add-on to the existing IVF protocol to improve efficacy by mediating a final or complete maturation or synchrony in the oo- cyte. Alternatively, MAS can be used to rescue oocytes in cycles that otherwise would be cancelled due to apparent FSH hyper response. In this instance, the responsible clinician would consider cancellation based on the estradiol profile, ultra- sonography (PCO like response) thus avoiding the hCG treatment. The oocytes are aspirated at the time around day 15-16 substituting hCG treatment. Apart from the additional maturation step with a MAS compound, the above IVF is performed the usual way. Since one expects that by the traditional IVF procedure the eggs had been matured sufficiently, one would not expect that it would have any additional effect to add this additional maturation step.
Most of the steps in the above treatment and procedure are performed in a known manner and the remaining steps are performed in a manner known per se. More details about the removal of the oocytes from follicles in the ovary, culturing of the isolated oocytes, the culture medium to be used, the fertilisation with sperm, and the transfer of the embryo to the fallopian tube can be found in the literature, for example, in US patent specification No. 5,693,534 which is hereby incorporated by reference.
According to this invention, the MAS compound is added to the culture medium used. In this medium, the amount of the MAS compound is in the range from about 0.01 to about 100 μM, preferably in the range from about 0.1 to about 100 μM.
A preferred reason for treating a woman, within a consecutive period of 30 days, with a hypothalamic hormone and/or a pituitary hormone or an agonist or antagonist thereof or an active derivative is to obtain multiple preovulatory follicles.
Hypothalamic hormones are hormones present in the human hypothalamus. Pituitary hormones are hormones present in the human pituitary gland. Gonadotropic hormones are hormones secreted by the anterior lobe of the pituitary in vertebras and by mammalian placenta, which control the activity of gonads. Chemically, they are glycoproteins. Examples of gonadotropic hormones are FSH, LH and chorion gonadotropin, e.g. human chorion gonadotropin (hereinafter designated hCG). FSH stimulates growth of ovarian follicles and their oocytes in ovary and the formation of spermatozoa in testis. FSH can, e.g., be menopausal FSH or recombinant FSH. In females, LH activates the oestrogen-producing tissue of the ovaries to produce progesterone, probably promotes the final stages of the development of ovarian follicles, initiates the final oocyte maturation, induces ovulation and in mammals initiates cor-
SUBSTΓΓUTE SHEET (RULE 26) pus luteum development. These hormones are known. It is obvious for the skilled art worker that, alternatively, agonists or antagonists of these hormones can be used. It is also obvious for the skilled art worker that, alternatively, active analogues of these hormones can be used. Some of these agonists, antagonists and analogues are known and other can be prepared by process known per se. Examples of such known processes are chemical synthesis and genetic engineering.
In a preferred embodiment, the present invention relates to a method or use wherein the consecutive period of 30 days within which the woman is treated with a hypotha- lamic hormone and/or a pituitary hormone or an agonist or antagonist thereof or an active derivative thereof is at least about 7 days, preferably at least about 10 days, more preferred at least about 14 days.
In another preferred embodiment, the present invention relates to a method or use wherein the woman is treated for infertility, and/or for improving the maturation of her oocytes, and/or for improving the synchrony of nuclear, cytoplasmic and/or membranous oocyte maturation, and/or for improving the fertility of her oocytes, and/or for improving the rate of implantation by human in vitro maturation and fertilisation
In another preferred embodiment, the present invention relates to a method or use wherein the consecutive period is one menstrual cycle.
In another preferred embodiment, the present invention relates to a method or use wherein the maturation of the oocytes with the MAS compound is for a duration of about 15 to about 60 hours.
In another preferred embodiment, the present invention relates to a method or use wherein preovulatory follicles are induced to lutenise with a luteinising hormone (LH) or an agonist or antagonist thereof or an active derivative thereof and/or human chorion gonadotropin (HCG) or an agonist or antagonist thereof or an active derivative thereof. In another preferred embodiment, the present invention relates to a method or use wherein the maturation of the oocytes with the MAS compound is for a duration of about 1 to about 15 hours, preferably about 6 hours.
In another preferred embodiment, the present invention relates to a method or use wherein the dosage of MAS compound used is about 0.01 to about 100 μmol per litre, preferably about 0.1 to about 100 μmol per litre.
In another preferred embodiment, the present invention relates to a method or use wherein the MAS compound is one of the compounds mentioned in WO 96/00235, 96/27658, 97/00884, 98/28323, 98/54965 and 98/55498, more specifically compounds mentioned in Claim 1 thereof.
In another preferred embodiment, the present invention relates to a method or use wherein the MAS compound is FF-MAS.
Additionally, the present invention relates to the use of a hypothalamic hormone and/or a pituitary hormone or an agonist or antagonist thereof or an active derivative thereof in the manufacture of a hormone product which is to be administered to a woman who, within a consecutive period of 30 days, is treated with a hypothalamic hormone and/or a pituitary hormone or an agonist or antagonist thereof or an active derivative thereof, and from whom, immediately after said period, one or more oocytes are aspirated, where after said oocyte(s) is/are cultivated in a convenient medium containing a MAS compound as defined herein, where after said oocyte(s) is/are fertilised with human sperm, and where after the resulting embryo(s) is/are transferred to a woman.
Additionally, the present invention relates to the use of a hypothalamic hormone and/or a pituitary hormone or an agonist or antagonist thereof or an active derivative thereof and of a MAS compound for the manufacture of a medicament for the treatment of human in vitro fertilisation wherein a hypothalamic hormone and/or a pituitary hormone or an agonist or antagonist thereof or an active derivative thereof is, within a consecutive period of 30 days, used to treat a women and, thereafter, the MAS compound is used in an in vitro oocyte maturation of the egg or eggs retrieved from this woman.
Additionally, the present invention relates to a pharmaceutically kit in unit dosage form for use by in vitro fertilisation comprising separate unit dosages, said kit comprising separate dosage units for sequential daily administration of a hypothalamic hormone and/or a pituitary hormone or an agonist or antagonist thereof or an active derivative thereof for sequential daily administration and 1 dosage units of a MAS compound. This kit may have the preferred features described above.
The present invention is further illustrated by the following examples, which, however, are not to be construed as limiting. The features disclosed in the foregoing description, in the following examples and in the claims may, both separately and in any combination thereof be material for realising the invention in diverse forms thereof.
Example 1
Method used for electing MAS compounds
Oocytes were obtained from immature female mice (C57BL/6J x DBA/2J F1 , Bom- holtgaard, Denmark) weighing 13-16 grams, that were kept under controlled tem- perature (20-22°C), light (lights on 06.00-18.00) and relative humidity (50-70%). The mice received an intra-peritoneal injection of 0.2 ml gonadotropins (Gonal-F, Serono) containing 20 IU FSH and 48 hours later the animals were killed by cervical dislocation. The ovaries were dissected out and the oocytes were isolated in Hx-medium (see below) under a stereomicroscope by manual rupture of the follicles using a pair of 27 gauge needles. Spherical oocytes displaying an intact germinal vesicle (hereinafter designated GV) were divided in cumulus enclosed oocytes (hereinafter designated CEO) and naked oocytes (hereinafter designated NO) and placed in α-
SUBSTΓΓUTE SHEET (RULE 26) minimum essential medium (α-MEM without ribonucleosides, Gibco BRL, Cat. No. 22561 ) supplemented with 3 mg/ml bovine serum albumin (BSA, Sigma Cat. No. A- 7030), 5 mg/ml human serum albumin (HSA, Statens Seruminstitut, Denmark), 0.23mM pyruvate (Sigma, Cat. No S-8636), 2 mM glutamine (Flow Cat. No. 16-801 ), 100 lU/ml penicillin and 100 μg/ml streptomycin (Flow, Cat No. 16-700). This medium was supplemented with 3 mM hypoxanthine (Sigma Cat. No. H-9377) and designated Hx-medium.
The oocytes were rinsed three times in Hx-medium and oocytes of uniform size were divided into groups of CEO and NO. CEO and NO were cultured in 4-well multidishes (Nunclon, Denmark) in which each well contained 0.4 ml of Hx-medium and the compound to be tested in a concentration of 10 μM. One control well (i.e., 35-45 oocytes cultured in identical medium with no addition of test compound) was always cultured simultaneously with 3 test wells (35-45 oocytes per well supplemented with test compound). The oocytes were cultured in a humidified atmosphere of 5% C02 in air for
24 hours at 37°C. By the end of the culture period, the number of oocytes with GV, GVB and polar bodies (hereinafter designated PB), respectively, were counted using a stereo microscope (Wildt, Leica MZ 12). The percentage of GVB, defined as percentage of oocytes undergoing GVB per total number of oocytes in that well, was calculated as:
% GVB = ((number of GVB + number of PB)/ total number of oocytes) X 100.
Example 2
Procedure
All IVF patients can potentially receive this treatment, age range 20 to 45 year. The hormonal treatment can be a short or long gonadotropin based treatment with or without pituitary down regulation or with and without the use of GNRH antagonist and with or without the use of hCG. Future appropriate hormonal therapies designed for IVF can also be used. Medium to full size follicles (size 10 to 25 mm, preferential 16 to 20 mm follicles) will be aspirated under ultrasound guidance. The aspirated fluid will be searched for cumulus oocytes complexes (COC) and once identified under the stereomicroscope (with or without the use of embryo filters), the COC will be placed in culture.
The exposure to FF-MAS can vary from 1 to 60 hours, preferentially from 4 to 30 hours, and can be before, under and up to 24 hours after fertilisation. A wide variety of oocyte culture media or media components known to the skilled worker can be used. Human serum albumin (HSA) may or may not be added to the medium. If added, it can be in a concentration of 0.1 to 100 mg/ml, preferentially 5 to 15 mg/ml or 0.5 to 1.5 % volume/volume. The formulation of FF-MAS may be in the form of an ethanol stock solution, DMSO or other organic solvent solution or it may be in form of FF-MAS/HSA dry coated wells ready to use just by adding the appropriate culture medium. The concentration of FF-MAS may vary from 0J μM to 100 μM, preferentially 10 to 30 μM.
Following or during in vitro culture with FF-MAS, the oocytes may be fertil- ised by conventional IVF or by intracytoplasmatic sperm injection (ICSI) or by future appropriate fertilisation methods leading to fertilised zygotes. The developing embryo may be transferred on day 1 to day 6 after fertilisation, preferentially on day 2 to 3, either as single egg transfer or multiple egg transfer.
The patient can receive progesterone and/or oestrogen therapy before and after the egg transfer in individually designed protocols to prime and sustain appropriate receptive endometrial lineage.
Compared with the know procedures, better results were obtained using the above procedure.
Example 3
Use of FF-MAS as adjunct to a standard FSH based IVF treatment
The patient underwent down regulation with recombinant FSH with an aver- age daily dose of 225 IU starting on Day 1 or 2 of the current cycle and used a GnRH antagonist, i.e., Cetrorelix (1 mg daily, subcutaneously, one shot), in the current cycle. At least 3 follicles of 17 mm or more were present at the time of administering hCG, i.e., Profasi (10.000 IU, one shot). Follicles were aspirated and metaphase II oocytes were cultured in oocyte culture system containing standard in vitro fertilization (IVF) media (IVF 20 (which is available from Scandinavian IVF Science AB, Gothenburg, Sweden)) supplemented with human serum albumin (0.8%) and FF- MAS (5 μM). All oocytes were cultured under normal conditions at 37°C in the incu- bator. Each oocyte was cultured in one well in a four-chamber culture dish as culture media system. The duration of exposure to the culture media with treatment was 4 hours (±30 minutes) before intracytoplasmic sperm injection (hereinafter designated ICSI) and 20 hours (±1 hour) after ICSI in the above IVF 20 medium. Preembryos were evaluated for cleavage stage and fragmentation / morphology at 1 , 2 and 3 days post ICSI. After 3 days of culture, a selection of the best preembryos, typically two preembryos, was replaced to the female patient. The female patient received an estrogen, i.e., Estrofem (6 mg/daily), and a progesterone, i.e. Utrogestan (600 mg/daily, micronized, vaginal suppository), to render the endometrium lining the patient uterus responsive and ready for allowing implantation of the transferred eggs. The continuation of supporting steroid hormones was patient depending and was seponated after 3-10 weeks depending on ultrasound scans and blood testing.
Compared with the know procedures, better results were obtained using the above procedure.
Example 4
Use of FF-MAS as adjunct to a standard FSH based IVF treatment
The patient underwent down regulation with an GnRH analog, i.e., Synarel (nasal spray, two puffs daily), for at least 14 days (starting in the luteal phase of the previous cycle or Day 1 or 2 in the follicular phase of the current cycle) and ovarian stimulation with recombinant FSH with an average daily dose of 225 IU. At least 3 follicles of 17 mm or more were present at the time of administering hCG, i.e. Profase (10.000 IU, one shot). Follicles were aspirated and metaphase II oocytes were cultured in oocyte culture system containing standard in vitro fertilization (IVF) media (IVF 20 (which is available from Scandinavian IVF Science AB, Gothenburg, Swe-
SUBSTΓΓUTE SHEET (RULE 26) den)) supplemented with human serum albumin (0.8%) and FF-MAS (5 μM). All oocytes were cultured under normal conditions at 37°C in the incubator. Each oocyte was cultured in one well in a four-chamber culture dish as culture media system. The duration of exposure to the culture media with treatment was 4 hours (+30 minutes) before intracytoplasmic sperm injection (ICSI) and 20 hours (±1 hour) after ICSI in the above IVF 20 medium. Preembryos were evaluated for cleavage stage and fragmentation / morphology at 1 , 2 and 3 days post ICSI. After 3 days of culture, a selection of the best preembryos, typically two preembryos, was replaced to the female patient. The female patient received an estrogen, i.e., Estrofem (6 mg/daily), and a progesterone, i.e., Utrogestan (600 mg/daily, micronized, vaginal suppository), daily to render the endometrium lining the patient uterus responsive and ready for allowing implantation of the transferred eggs. The continuation of supporting steroid hormones was patient depending and was seponated after 3-10 weeks depending on ultrasound scans and blood testing. Compared with the know procedures, better results were obtained using the above procedure.
Example 5
Using the procedure described in Example 3 with the proviso that in stead of using FF-MAS in a concentration of 5 μM, FF-MAS was used in a concentration of 20 μM, better results were obtained than with the know procedures.
Example 6
Using the procedure described in Example 4 with the proviso that in stead of using FF-MAS in a concentration of 5 μM, FF-MAS was used in a concentration of 20 μM, better results were obtained than with the know procedures.

Claims

1. A method for human in vitro fertilisation wherein a woman, within a consecutive period of 30 days, is treated with a hypothalamic hormone and/or a pituitary hormone or an agonist or antagonist thereof or an active derivative thereof where after oocytes are aspirated and actively matured or synchronised in vitro in contact with a MAS compound.
2. The use of a hypothalamic hormone and/or a pituitary hormone or an agonist or antagonist thereof or an active derivative thereof in the manufacture of a hormone product which is to be administered to a woman who, within a consecutive period of 30 days, is treated with a hypothalamic hormone and/or a pituitary hormone or an agonist or antagonist thereof or an active derivative thereof, and from whom, immediately after said period, one or more oocytes are aspirated, where after said oocyte(s) is/are cultivated in a convenient medium containing a
MAS compound as defined herein, where after said oocyte(s) is/are fertilised with human sperm, and where after the resulting embryo(s) is/are transferred to a woman.
3. Use of a hypothalamic hormone and/or a pituitary hormone or an agonist or antagonist thereof or an active derivative thereof and of a MAS compound for the manufacture of a medicament for the treatment of human in vitro fertilisation wherein a hypothalamic hormone and/or a pituitary hormone or an agonist or antagonist thereof or an active derivative thereof is, within a consecutive period of 30 days, used to treat a women and, thereafter, the MAS compound is used in an in vitro oocyte maturation of the egg or eggs retrieved from this woman.
4. A method or use according to any one of the preceding claims wherein the woman is treated for infertility, and/or for improving the maturation of her oo- cytes, and/or for improving the synchrony of nuclear, cytoplasmic and/or membranous oocyte maturation, and/or for improving the fertility of her oocytes, and/or for improving the rate of implantation by human in vitro maturation and fertilisation
5. A method or use according to any one of the preceding claims wherein the con- secutive period of 30 days within which the woman is treated with a hypothalamic hormone and/or a pituitary hormone or an agonist or antagonist thereof or an active derivative thereof is at least about 7 days, preferably at least about 10 days, more preferred at least about 14 days.
6. A method or use according to any one of the preceding claims wherein the consecutive period is one menstrual cycle.
7. A method or use according to the previous claim wherein the maturation of the oocytes with the MAS compound is for a duration of about 15 to about 60 hours.
8. A method or use according to any one of the preceding claims wherein preovulatory follicles are induced to lutenise with a luteinising hormone (LH) or an agonist or antagonist thereof or an active derivative thereof and/or human chorion gonadotropin (HCG) or an agonist or antagonist thereof or an active derivative thereof.
9. A method or use according to the previous claim wherein the maturation of the oocytes with the MAS compound is for a duration of about 1 to about 15 hours, preferably about 6 hours.
10. A method or use according to any one of the previous claims wherein the dosage of MAS compound is about 0.01 to about 100 μmol per litre, preferably about 0.1 to about 100 μmol per litre.
1 1. A method or use according to any one of the previous claims, wherein the MAS compound is one of the compounds mentioned in WO 96/00235, 96/27658, 97/00884, 98/28323, 98/54965 and 98/55498, more specifically compounds mentioned in Claim 1 thereof.
12. A method or use according to the previous claim wherein the MAS compound is 5 FF-MAS.
13. A pharmaceutically kit in unit dosage form for use by in vitro fertilisation comprising separate unit dosages, said kit comprising separate dosage units for sequential daily administration of a hypothalamic hormone and/or a pituitary hormone or o an agonist or antagonist thereof or an active derivative thereof for sequential daily administration and 1 dosage units of a MAS compound.
14. A kit according to the previous claim having the preferred features described in any one of the above subclaims. 5
15. Any novel feature or combination of features described herein.
PCT/DK2000/000074 1999-02-24 2000-02-23 Treatment of infertility WO2000050066A1 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
JP2000600676A JP2002537349A (en) 1999-02-24 2000-02-23 Treatment of infertility
BR0008468-9A BR0008468A (en) 1999-02-24 2000-02-23 Method for human in vitro fertilization, use of a hypothalamic hormone and / or pituitary hormone or an agonist or antagonist of the same or an active derivative thereof, pharmaceutical kit in single dosage form, and any new aspect or combination of aspects
KR1020017009383A KR20010093280A (en) 1999-02-24 2000-02-23 Treatment of infertility
EP00906178A EP1156822B1 (en) 1999-02-24 2000-02-23 Iin vitro method for synchronisation of oocyte maturation
DE60025905T DE60025905T2 (en) 1999-02-24 2000-02-23 IN VITRO METHOD FOR THE SYNCHRONIZATION OF OXYGEN TREATMENT
PL00350221A PL350221A1 (en) 1999-02-24 2000-02-23 Treatment of infertility
IL14372900A IL143729A0 (en) 1999-02-24 2000-02-23 Treatment of infertility
CA002362940A CA2362940A1 (en) 1999-02-24 2000-02-23 Treatment of infertility
AU27941/00A AU2794100A (en) 1999-02-24 2000-02-23 Treatment of infertility
US09/528,610 US6585982B1 (en) 1999-02-24 2000-03-20 Treatment of infertility
NO20014093A NO20014093L (en) 1999-02-24 2001-08-23 Treatment of infertility

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DKPA199900255 1999-02-24
DKPA199900255 1999-02-24
US13081699P 1999-04-23 1999-04-23
US60/130,816 1999-04-23
DKPA199901310 1999-09-16
DKPA199901310 1999-09-16

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/528,610 Continuation US6585982B1 (en) 1999-02-24 2000-03-20 Treatment of infertility

Publications (1)

Publication Number Publication Date
WO2000050066A1 true WO2000050066A1 (en) 2000-08-31

Family

ID=27220546

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2000/000074 WO2000050066A1 (en) 1999-02-24 2000-02-23 Treatment of infertility

Country Status (13)

Country Link
US (1) US6585982B1 (en)
EP (1) EP1156822B1 (en)
JP (1) JP2002537349A (en)
KR (1) KR20010093280A (en)
CN (1) CN1353617A (en)
AT (1) ATE317266T1 (en)
AU (1) AU2794100A (en)
BR (1) BR0008468A (en)
CZ (1) CZ20012967A3 (en)
DE (1) DE60025905T2 (en)
ES (1) ES2258445T3 (en)
HU (1) HUP0200157A3 (en)
WO (1) WO2000050066A1 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001062260A2 (en) * 2000-02-25 2001-08-30 Schering Aktiengesellschaft Improvement of implantation rate
WO2001062258A2 (en) * 2000-02-25 2001-08-30 Schering Aktiengesellschaft Improvement of implantation rate using ff-mas
WO2001088098A2 (en) * 2000-05-18 2001-11-22 Schering Aktiengesellschaft Fertilization of aged oocytes
EP1216701A1 (en) * 2000-12-22 2002-06-26 Schering Aktiengesellschaft Process to increase the concentration of meiosis-activating sterols (MAS) in the cholesterol synthesis and the use of potent inhibitors in the process
WO2003022303A2 (en) * 2001-09-12 2003-03-20 Applied Research Systems Ars Holding N.V. Use of hcg and lh in controlled ovarian hyperstimulation
WO2003022302A2 (en) * 2001-09-12 2003-03-20 Applied Research Systems Ars Holding N.V. USE OF hCG IN CONTROLLED OVARIAN HYPERSTIMULATION
WO2003070766A2 (en) * 2002-02-22 2003-08-28 Novo Nordisk A/S A transducer of mas signalling
US6916921B2 (en) 2001-03-26 2005-07-12 Schering Ag Steroid compounds, use of these compounds for the preparation of meiosis-regulating medicaments and method for the preparation of these compounds
AU2002324183B2 (en) * 2001-09-12 2007-10-25 Merck Serono Sa Use of hCG and LH in controlled ovarian hyperstimulation
US7790459B2 (en) 2002-03-08 2010-09-07 Mcgill University In vitro maturation of immature human oocytes

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828415B2 (en) * 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
BR0008536A (en) * 1999-02-26 2001-11-06 Novo Nordisk As Uses of a culture medium, and at least one apple, analog of apples or an additive or additives, and, process for in vitro fertilization
AU2001261968A1 (en) * 2000-05-25 2001-12-03 Oregon Health Sciences University Pt32 sperm protein, sperm c-yes, oocyte cytoplasmic c-yes, and uses thereof
EP1511537B1 (en) * 2002-06-07 2012-11-21 Ares Trading S.A. Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method
EP3498827A1 (en) 2004-05-17 2019-06-19 The General Hospital Corporation Compositions comprising female germline stem cells and methods of use thereof
AU2007257594B2 (en) 2006-03-07 2012-11-01 Geeta Shroff Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation
CN103562378B (en) 2011-04-14 2016-09-07 通用医疗公司 Composition and method for the transfer of autologous germline mitochondria energy
EP2726601B1 (en) 2011-06-29 2018-12-26 The General Hospital Corporation Compositions and methods for enhancing bioenergetic status in female germ cells
US20150272622A1 (en) 2011-12-22 2015-10-01 Previvo Genetics, Llc Recovery and processing of human embryos formed in vivo

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994019455A1 (en) * 1993-02-23 1994-09-01 Genentech, Inc. In vitro maturation of oocytes with inhibin, activin or inhibin/activin combinations
WO1996000235A1 (en) * 1994-06-23 1996-01-04 Novo Nordisk A/S Sterol derivatives used for regulation of meiosis
WO1996027658A1 (en) * 1995-03-06 1996-09-12 Novo Nordisk A/S Stimulation of meiosis
WO1997000884A1 (en) * 1995-06-23 1997-01-09 Novo Nordisk A/S Meiosis regulating compounds
WO1997000883A1 (en) * 1995-06-23 1997-01-09 Novo Nordisk A/S Meiosis regulating compounds
WO1998028323A1 (en) * 1996-12-20 1998-07-02 Novo Nordisk A/S Meiosis regulating compounds
WO1998055498A1 (en) * 1997-06-04 1998-12-10 Akzo Nobel N.V. 17β-ALLYLOXY(THIO)ALKYL-ANDROSTANE DERIVATIVES FOR THE MODULATION OF MEIOSIS
WO1998054965A1 (en) * 1997-06-06 1998-12-10 Basf Aktiengesellschaft Fungicidal mixtures

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000050065A1 (en) * 1999-02-24 2000-08-31 Novo Nordisk A/S Treatment of infertility

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994019455A1 (en) * 1993-02-23 1994-09-01 Genentech, Inc. In vitro maturation of oocytes with inhibin, activin or inhibin/activin combinations
WO1996000235A1 (en) * 1994-06-23 1996-01-04 Novo Nordisk A/S Sterol derivatives used for regulation of meiosis
WO1996027658A1 (en) * 1995-03-06 1996-09-12 Novo Nordisk A/S Stimulation of meiosis
WO1997000884A1 (en) * 1995-06-23 1997-01-09 Novo Nordisk A/S Meiosis regulating compounds
WO1997000883A1 (en) * 1995-06-23 1997-01-09 Novo Nordisk A/S Meiosis regulating compounds
WO1998028323A1 (en) * 1996-12-20 1998-07-02 Novo Nordisk A/S Meiosis regulating compounds
WO1998055498A1 (en) * 1997-06-04 1998-12-10 Akzo Nobel N.V. 17β-ALLYLOXY(THIO)ALKYL-ANDROSTANE DERIVATIVES FOR THE MODULATION OF MEIOSIS
WO1998054965A1 (en) * 1997-06-06 1998-12-10 Basf Aktiengesellschaft Fungicidal mixtures

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SMITZ, JOHAN ET. AL.: "Oocyte in-vitro maturation and follicle culture: current clinical achievments and future directions", HUMAN REPRODUCTION, vol. 14, no. 1, 1999, pages 145 - 161, XP002929268 *

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001062260A2 (en) * 2000-02-25 2001-08-30 Schering Aktiengesellschaft Improvement of implantation rate
WO2001062258A2 (en) * 2000-02-25 2001-08-30 Schering Aktiengesellschaft Improvement of implantation rate using ff-mas
WO2001062258A3 (en) * 2000-02-25 2002-03-07 Schering Ag Improvement of implantation rate using ff-mas
WO2001062260A3 (en) * 2000-02-25 2002-04-04 Schering Ag Improvement of implantation rate
WO2001088098A2 (en) * 2000-05-18 2001-11-22 Schering Aktiengesellschaft Fertilization of aged oocytes
WO2001088098A3 (en) * 2000-05-18 2002-05-16 Schering Ag Fertilization of aged oocytes
EP1216701A1 (en) * 2000-12-22 2002-06-26 Schering Aktiengesellschaft Process to increase the concentration of meiosis-activating sterols (MAS) in the cholesterol synthesis and the use of potent inhibitors in the process
US6916921B2 (en) 2001-03-26 2005-07-12 Schering Ag Steroid compounds, use of these compounds for the preparation of meiosis-regulating medicaments and method for the preparation of these compounds
WO2003022302A3 (en) * 2001-09-12 2003-12-18 Applied Research Systems USE OF hCG IN CONTROLLED OVARIAN HYPERSTIMULATION
WO2003022302A2 (en) * 2001-09-12 2003-03-20 Applied Research Systems Ars Holding N.V. USE OF hCG IN CONTROLLED OVARIAN HYPERSTIMULATION
WO2003022303A3 (en) * 2001-09-12 2003-12-18 Applied Research Systems Use of hcg and lh in controlled ovarian hyperstimulation
WO2003022303A2 (en) * 2001-09-12 2003-03-20 Applied Research Systems Ars Holding N.V. Use of hcg and lh in controlled ovarian hyperstimulation
AU2002324183B2 (en) * 2001-09-12 2007-10-25 Merck Serono Sa Use of hCG and LH in controlled ovarian hyperstimulation
EA009279B1 (en) * 2001-09-12 2007-12-28 Апплайд Резеч Системз Арс Холдинг Н.В. Use of human chorionic gonadotropin for use in conjunction with follicle stimulating hormone for aiding implantation and/or decreasing miscarriage rates
EA009330B1 (en) * 2001-09-12 2007-12-28 Апплайд Резеч Системз Арс Холдинг Н.В. Method encouraging implantation rates and/or decreased miscarriage rates and kit therefor
CN100376289C (en) * 2001-09-12 2008-03-26 应用研究系统Ars股份公司 Use of HCG and LH in controlled ovarian hyperstimulation
US7402558B2 (en) 2001-09-12 2008-07-22 Laboratoires Seronosa Method for aiding implantation or decreasing miscarriage rate
US7405197B2 (en) 2001-09-12 2008-07-29 Laboratories Serono Sa Use of hCG in controlled ovarian hyperstimulation
WO2003070766A2 (en) * 2002-02-22 2003-08-28 Novo Nordisk A/S A transducer of mas signalling
WO2003070766A3 (en) * 2002-02-22 2003-12-24 Novo Nordisk As A transducer of mas signalling
US7790459B2 (en) 2002-03-08 2010-09-07 Mcgill University In vitro maturation of immature human oocytes

Also Published As

Publication number Publication date
US6585982B1 (en) 2003-07-01
ES2258445T3 (en) 2006-09-01
HUP0200157A3 (en) 2002-06-28
EP1156822A1 (en) 2001-11-28
KR20010093280A (en) 2001-10-27
DE60025905D1 (en) 2006-04-20
CZ20012967A3 (en) 2001-12-12
CN1353617A (en) 2002-06-12
JP2002537349A (en) 2002-11-05
EP1156822B1 (en) 2006-02-08
AU2794100A (en) 2000-09-14
DE60025905T2 (en) 2006-09-14
BR0008468A (en) 2002-02-05
ATE317266T1 (en) 2006-02-15
HUP0200157A2 (en) 2002-05-29

Similar Documents

Publication Publication Date Title
US6281013B1 (en) Treatment of Infertility
US6585982B1 (en) Treatment of infertility
US5869081A (en) Progesterone vaginal ring for treatment of infertility
Zhang et al. Effects of follicle‐stimulating hormone and ovarian steroids during vitro meiotic maturation on fertilization of rat oocytes
KR20120023097A (en) Methods for the collection and maturation of oocytes
Crawford et al. The hypothalamic–pituitary–ovarian axis and manipulations of the oestrous cycle in the brushtail possum
Zanagnolo et al. Effects of a gonadotropin-releasing hormone analog on rabbit ovarian function
EP1235899B1 (en) Treatment of human infertility
Rizk et al. Clinical infertility and in vitro fertilization
CA2362940A1 (en) Treatment of infertility
ZA200104803B (en) Treatment of infertility.
US6544166B1 (en) Treatment of human infertility
Serhal Oocyte donation and surrogacy
Bernardini et al. Pregnancy: Pregnancy and implantation rates in normal replacement versus stimulated cycles
Birkenfeld et al. The effect of clomiphene citrate on blastocyst development and implantation in the rabbit
ZA200104653B (en) Treatment of infertility.
JP2002531414A (en) Improve follicle development
JP2003529378A (en) In vitro maturation methods for cytoplasmic and nuclear maturation of oocytes
MXPA01008452A (en) Treatment of infertility
Buckett et al. In vitro maturation of oocytes
Dhanda et al. Ovarian hormones and their role in oestrous cycle in animals: A review
Wehrman Development of a persistent ovarian follicle during estrous synchronization affects fertility and follicular recruitment in cattle
Serhal Oocyte donation
US20030153808A1 (en) Implantation rate using ff-mas

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 00804135.0

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 09528610

Country of ref document: US

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001/04803

Country of ref document: ZA

Ref document number: 143729

Country of ref document: IL

Ref document number: 200104803

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 27941/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000906178

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020017009383

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2001/1124/CHE

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: PV2001-2967

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/008456

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2362940

Country of ref document: CA

Ref document number: 2362940

Country of ref document: CA

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2000 600676

Country of ref document: JP

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1020017009383

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2000906178

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV2001-2967

Country of ref document: CZ

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1020017009383

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 2000906178

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV2001-2967

Country of ref document: CZ